Absci (ABSI) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Absci (ABSI) has outperformed Pharvaris N.V. (PHVS) over the past year, gaining 153.4% versus a gain of 36.2%. Over five years, PHVS leads with a +96.8% price change compared with -4.4% for ABSI. Pharvaris N.V. is the larger company by market cap ($2.18 billion vs $1.74 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | PHVS |
|---|---|---|
| Share price | $10.16 | $31.10 |
| Market cap | $1.74B | $2.18B |
| 1-day change | +13.65% | -0.06% |
| YTD return | +191.12% | +12.07% |
| 1-year return | +153.37% | +36.16% |
| 5-year return | -4.42% | +96.84% |
| EPS (TTM) | $-0.79 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | — |
| Revenue growth (YoY) | -38.24% | — |
| Net income (latest FY) | $-115.18M | $-25.99M |
| Operating margin | -4297.04% | — |
| Net margin | -4113.68% | — |
| 52-week high | $12.06 | $43.25 |
| 52-week low | $2.24 | $20.65 |
| Distance from 52-week high | -15.72% | -28.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +41.73% | +84.47% |
| Average volume | 3.43M | 711.75K |
| Shares outstanding | 171.61M | 70.20M |
| Employees | 140 | 148 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed PHVS by 117.2 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Healthcare · Biotechnology · 140 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Healthcare · Biotechnology · 148 employees
ABSI vs PHVS FAQ
Which is bigger, Absci or Pharvaris N.V.?
Pharvaris N.V. (PHVS) is larger, with a market capitalization of $2.18B compared with $1.74B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or PHVS?
ABSI returned +153.37% over the past 12 months, compared with +36.16% for PHVS (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Pharvaris N.V. in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.